Vilaterm F Inhaler represents a new benchmark in the management of chronic respiratory diseases, offering a powerful triple-combination therapy in a single device. It contains a precise dose of three active components: Vilanterol (25 mcg), a long-acting beta-2 agonist (LABA); Fluticasone (100 mcg), an inhaled corticosteroid (ICS); and Glycopyrronium (25 mcg), a long-acting muscarinic antagonist (LAMA). This synergistic blend provides a three-pronged attack on severe COPD, targeting both the underlying airway inflammation and the mechanisms of bronchoconstriction, resulting in improved lung function, reduced symptoms, and a significant decrease in the risk of exacerbations.
The market for advanced respiratory treatments in India is a high-demand, high-value sector with a strong growth trajectory. The increasing prevalence of severe COPD, fueled by factors such as rising air pollution and an aging population, ensures a continuous and robust need for effective, cutting-edge therapies. As a premium product in the pulmonology segment, Vilaterm F Inhaler commands a stable prescription base from specialists. Its essential nature for long-term chronic disease management guarantees a steady and predictable revenue stream, making it a strategic and highly profitable choice for any distributor.
We are dedicated to empowering our franchise partners with all the tools necessary for success in this specialized market. Our product, manufactured in a WHO-GMP certified facility, ensures impeccable quality, efficacy, and safety, which is crucial for building trust with pulmonologists and patients. We provide a complete promotional and marketing kit, including visual aids and product literature, to support your sales efforts. Our robust supply chain guarantees timely delivery and continuous stock availability, preventing any business interruptions. Partner with us to enter this stable and highly profitable market and establish a reputable and successful business as a key supplier of this top-quality respiratory medicine.